What is Bristol-Myers Squibb Company's stock symbol?
Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company announced a quarterly dividend on Thursday, December 8th. Stockholders of record on Friday, January 6th will be paid a dividend of $0.39 per share on Wednesday, February 1st. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date is Wednesday, January 4th. This is a boost from Bristol-Myers Squibb Company's previous quarterly dividend of $0.38.
Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?
20 analysts have issued 12 month target prices for Bristol-Myers Squibb Company's stock. Their predictions range from $42.00 to $75.00. On average, they expect Bristol-Myers Squibb Company's stock price to reach $61.83 in the next year.
When will Bristol-Myers Squibb Company announce their earnings?
Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Bristol-Myers Squibb Company stock?
Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:
- Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)
- BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)
SunTrust Banks, Inc. analysts commented, "Our '17E EPS decreases to $3.02 (from $3.29) vs. Street's $3.00. We lowered our PT to $62 (from $68) & maintained our Hold rating. Our $62PT is based on 20x our '17E EPS. BMY needs positive expressers arm of CM-227 to stop in 2017 for it to execute on its IO-IO combo strategy."On October 9, Bristol-Myer disclosed in a statement, "Two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of previously treated metastatic non-small cell lung cancer (NSCLC) patients in both trials experienced ongoing responses with Opdivo, compared to no ongoing responses in the docetaxel arm." (10/10/2016)
Who owns Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.05%), FMR LLC (2.71%), Janus Capital Management LLC (1.19%), Loomis Sayles & Co. L P (0.82%), Bessemer Group Inc. (0.20%) and New York State Teachers Retirement System (0.18%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Francis M Cuss, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler and Sandra Leung.
Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Janus Capital Management LLC, Fred Alger Management Inc., FMR LLC, RidgeWorth Capital Management LLC, Orbimed Advisors LLC, FIL Ltd and William Blair Investment Management LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler and Sandra Leung.
Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?
Bristol-Myers Squibb Company's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Asset Management One Co. Ltd., Bessemer Group Inc., AMF Pensionsforsakring AB, Congress Asset Management Co. MA, RTW Investments LP, Ardevora Asset Management LLP and Franklin Resources Inc..
How do I buy Bristol-Myers Squibb Company stock?
Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bristol-Myers Squibb Company stock cost?
One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $55.35.